Pharmaceutical giant Lupin has reaffirmed its dedication to sustainability with significant advancements in its Environmental, Social, and Governance (ESG) strategy, positioning itself as a leader in sustainable healthcare solutions. At the core of Lupin’s operations lies a robust sustainability framework, driving the company’s efforts to achieve net-zero emissions, enhance social impact, and maintain the highest standards of governance.

Lupin has made notable strides in environmental stewardship, reporting a 21% reduction in carbon emissions and increasing its reliance on renewable energy to 33.8% over the last year. Additionally, the company has achieved water positivity across all its operations, underlining its commitment to addressing climate change and resource management. These efforts are complemented by initiatives focused on water recycling, the circular economy, biodiversity assessment, and life cycle assessments (LCA).

Ramesh Swaminathan, Executive Director, Global CFO, and Head of API Plus SBU at Lupin, emphasized the company’s ESG progress. “We have made significant progress in our Environmental, Social, and Governance goals over the last four years. The S&P score reaffirms our commitment to prioritizing sustainability and creating impactful and sustainable healthcare solutions that benefit our patients and our communities worldwide,” he stated.

In the social domain, Lupin has prioritized diversity, equity, and inclusion (DEI) in the workplace, alongside initiatives for employee well-being and supply chain sustainability. Furthermore, the company continues to advance patient-centric innovation, delivering healthcare solutions that align with its sustainability ethos.

Lupin’s comprehensive approach underscores its vision for a sustainable and equitable future, serving as a benchmark for the pharmaceutical industry in responsible business practices.